Head-to-head evidence
efpeglenatide vs Supaglutide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: GLP-1 receptor · full Type 2 Diabetes pipeline
efpeglenatide
Developed by Hanmi Pharmaceutical and partners
NCT03353350 · Phase 3 · completed
The trial was randomized, quadruple-blinded, placebo-controlled, and included 406 participants, providing a strong comparative design. However, the primary endpoint was the surrogate measure of HbA1c change, and although the reported changes favored efpeglenatide, statistical significance for the primary comparison was not reported.
Next expected readout: November 2027 · NCT07379333 (registry estimate)
Supaglutide
Developed by Shanghai Yinnuo Pharmaceutical Technology
NCT04998032 · Phase 2/3 · completed
In this randomized, double-blind, placebo-controlled Phase 2b/3 trial in 620 adults with type 2 diabetes already taking metformin, adding once-weekly supaglutide significantly lowered blood-sugar control (HbA1c) at 24 weeks compared with adding placebo, with a clearly significant treatment difference.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: efpeglenatide's landscape · Supaglutide's landscape